Qt Imaging Holdings Stock Earnings Reports

QT Imaging reported strong operational progress in Q1 2026 driven by commercialization, regulatory and software milestones. The company shipped 13 QT Breast Acoustic CT systems in the quarter and announced a two-year extension of its senior secured term loan maturity (to March 31, 2029). Key regulatory and reimbursement wins include FDA 510(k) clearance for posterior breast tissue imaging enhancements, UAE regulatory clearance, and AMA approval of a new Category III CPT code (effective Jan 1, 2027). Software advances included the QT Imaging–Olea Viewer and software version 4.5.0 (notable ~40–50% improvement in reflection-image resolution), which management expects to improve detection (including calcifications) and support longitudinal/therapy response applications. Financially, Q1 revenue was $6.5M (up 133% YoY) with gross margin of 41% and net loss reduced to $3.4M (vs. $11.1M prior year). Adjusted EBITDA was negative $1.5M. Cash and equivalents were $7.0M at quarter end. Management reaffirmed 2026 revenue guidance of approximately $39M, supported by distributor contracts (NXC Imaging, Gulf Medical, Al Naghi) and anticipated monetization of cloud/SaaS services. International expansion (Gulf region, UAE, Saudi SFDA pending, Israel AMAR, CE Mark timeline) and clinical validation (Mayo Clinic, Sunnybrook tumor response data) remain priorities.